SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10795	Companies
233330	Keywords
161979	Articles
124515	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/23/2025 at 07:00, 1 year 1 month ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF

published on 06/20/2025 at 07:05, 1 year 1 month ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
PRESS RELEASE

published on 06/20/2025 at 07:00, 1 year 1 month ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease

FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
BRIEF

published on 06/17/2025 at 13:45, 1 year 1 month ago

Sanofi Successfully Prices €1.5 Billion Bond Issue

Bond Issue Corporate Financing Sanofi Fixed-rate Notes Euro Medium Term Note
PRESS RELEASE

published on 06/17/2025 at 13:40, 1 year 1 month ago

Press release: Sanofi successfully prices €1.5 billion bond issue
Sanofi successfully prices €1.5 billion bond issue with fixed-rate notes across 2 tranches, using proceeds for general corporate purposes, led by Citigroup and RBC Capital Markets, under Euro Medium Term Note Programme

Financial Markets Bond Issue Sanofi Euro Medium Term Note Programme Fixed-rate Notes
PRESS RELEASE

published on 06/16/2025 at 22:40, 1 year 1 month ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 06/15/2025 at 17:27, 1 year 1 month ago

Sanofi's Dupixent Surpasses Xolair in Phase 4 Study for Chronic Rhinosinusitis with Asthma

Sanofi Dupixent Phase 4 Study CRSwNP Asthma
PRESS RELEASE

published on 06/15/2025 at 17:22, 1 year 1 month ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and coexisting asthma, showing superior efficacy across all key endpoints in a phase 4 study presented at EAACI

Dupixent Phase 4 Study Asthma Xolair Chronic Rhinosinusitis
BRIEF

published on 06/09/2025 at 23:14, 1 year 1 month ago

Sanofi Releases May 2025 Voting Rights and Shares Data

Voting Rights Shares Regulatory Compliance France Sanofi
PRESS RELEASE

published on 06/09/2025 at 23:09, 1 year 1 month ago

Sanofi: Information concerning the total number of voting rights and shares - May 2025
Sanofi discloses total voting rights and shares information in compliance with French regulations. Details available on Sanofi's investor relations website

Voting Rights Shares French Regulations Investor Relations Sanofi

Accesswire

Published on 08/01/2026 at 01:20, 2 days 16 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 16 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 17 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 17 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 18 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 17:59, 3 minutes ago

Original-Research: Reply SpA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 08/03/2026 at 17:45, 17 minutes ago

Key Figures 31.07.2026
Published on 08/03/2026 at 16:45, 1 hour 17 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights, Issue of Shares and Treasury Shares
Published on 08/03/2026 at 16:45, 1 hour 17 minutes ago

Thailand - Canada Pilot Carbon Capture in Cement Industry to Advance Net Zero 2050
Published on 08/03/2026 at 16:38, 1 hour 23 minutes ago

BVB Japan Tour 2026: Record Reach, 70,000 Fan Contacts and Strong Commercial Momentum

Les Echos

Published on 08/03/2026 at 18:00, 2 minutes ago

H1 2026 revenue
Published on 08/03/2026 at 17:45, 17 minutes ago

Monthly disclosure of the total number of shares and voting rights - July 2026
Published on 08/03/2026 at 17:45, 17 minutes ago

Weekly share buyback
Published on 08/03/2026 at 17:40, 22 minutes ago

Eiffage announces the end of exclusive negotiations with Atlas Arteria for the possible acquisition of the Warnow Tunnel concession in Rostock, Germany
Published on 08/03/2026 at 17:35, 27 minutes ago

Disclosure of transactions in own shares from July 27 to July 31, 2026

View all LES ECHOS COMFI WIRE